TrialThe Lancet. Respiratory medicine2025

Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial.

Dave Singh et al.PubMed ↗Publisher ↗

No numbers read from the abstract.